epsilonaminocaproic
acid
eaca
a
therapeutic
agent
based
years
clinical
experience
experience
treatment
patients
eaca
suggested
use
preparation
indicated
following
situations
fibrinolytic
haemorrhage
association
delivery
acute
systemic
fibrinolysis
association
surgery
mainly
major
operations
thorax
pancreas
prostate
liver
genital
organs
complicated
fibrinolysis
fibrinolytic
bleedings
occur
operation
acute
systemic
fibrinolysis
patients
cancer
particularly
cancer
prostate
pancreas
systemic
fibrinolytic
states
complicating
various
disorders
especially
leukaemia
liver
cirrhosis
boecks
sarcoid
antidote
thrombolytic
therapy
local
fibrinolytic
activity
urinary
tract
following
situations
a
prostatectomy
eaca
substantially
reduce
blood
losses
following
prostatectomy
especially
treatment
continued
urine
become
macroscopically
clear
b
haematuria
prostatic
cancer
prostatic
hyperplasia
prolonged
haematuria
traumatic
injury
kidney
haematuria
haemophilia
coagulation
defects
socalled
essential
haematuria
ulcerative
colitis
drug
equally
effective
whether
given
orally
intravenously
states
increased
systemic
fibrinolytic
activity
a
dose
g
per
kg
body
weight
every
hours
recommended
inhibition
local
fibrinolytic
activity
urinary
tract
a
dose
g
three
times
a
day
proved
sufficient
sideeffects
consisted
dizziness
nausea
diarrhoea
toxic
effects
drug
e.c.g
blood
picture
n.p.n
liver
function
tests
observed
even
cases
receiving
g
eaca
postmortem
examination
cases
reveal
signs
a
toxic
effect
signs
intravascular
coagulation
connection
eaca
therapy
observed
incidence
thromboembolic
complications
prostatectomy
patients
treated
eaca
a
series
controls
identical
judging
authors
experience
material
eaca
act
agent
inducing
thrombosis
